JP2007525503A5 - - Google Patents

Download PDF

Info

Publication number
JP2007525503A5
JP2007525503A5 JP2007500824A JP2007500824A JP2007525503A5 JP 2007525503 A5 JP2007525503 A5 JP 2007525503A5 JP 2007500824 A JP2007500824 A JP 2007500824A JP 2007500824 A JP2007500824 A JP 2007500824A JP 2007525503 A5 JP2007525503 A5 JP 2007525503A5
Authority
JP
Japan
Prior art keywords
compound
formula
aliphatic
disease
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007500824A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007525503A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/006540 external-priority patent/WO2005085236A2/en
Publication of JP2007525503A publication Critical patent/JP2007525503A/ja
Publication of JP2007525503A5 publication Critical patent/JP2007525503A5/ja
Pending legal-status Critical Current

Links

JP2007500824A 2004-02-27 2005-02-28 カスパーゼインヒビターおよびそれらの使用 Pending JP2007525503A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US54861004P 2004-02-27 2004-02-27
US62974304P 2004-11-19 2004-11-19
US62966104P 2004-11-19 2004-11-19
PCT/US2005/006540 WO2005085236A2 (en) 2004-02-27 2005-02-28 Caspase inhibitors and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011095553A Division JP2011144203A (ja) 2004-02-27 2011-04-21 カスパーゼインヒビターおよびそれらの使用

Publications (2)

Publication Number Publication Date
JP2007525503A JP2007525503A (ja) 2007-09-06
JP2007525503A5 true JP2007525503A5 (cg-RX-API-DMAC7.html) 2008-04-03

Family

ID=34923260

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2007500824A Pending JP2007525503A (ja) 2004-02-27 2005-02-28 カスパーゼインヒビターおよびそれらの使用
JP2011095553A Withdrawn JP2011144203A (ja) 2004-02-27 2011-04-21 カスパーゼインヒビターおよびそれらの使用
JP2014097786A Pending JP2014140385A (ja) 2004-02-27 2014-05-09 カスパーゼインヒビターおよびそれらの使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2011095553A Withdrawn JP2011144203A (ja) 2004-02-27 2011-04-21 カスパーゼインヒビターおよびそれらの使用
JP2014097786A Pending JP2014140385A (ja) 2004-02-27 2014-05-09 カスパーゼインヒビターおよびそれらの使用

Country Status (16)

Country Link
US (2) US7652153B2 (cg-RX-API-DMAC7.html)
EP (2) EP2270004A1 (cg-RX-API-DMAC7.html)
JP (3) JP2007525503A (cg-RX-API-DMAC7.html)
KR (1) KR20060129069A (cg-RX-API-DMAC7.html)
CN (1) CN102161656B (cg-RX-API-DMAC7.html)
AR (1) AR047981A1 (cg-RX-API-DMAC7.html)
AU (1) AU2005219861B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0508102A (cg-RX-API-DMAC7.html)
CA (1) CA2557645C (cg-RX-API-DMAC7.html)
IL (1) IL177709A0 (cg-RX-API-DMAC7.html)
NO (2) NO20064344L (cg-RX-API-DMAC7.html)
NZ (1) NZ549665A (cg-RX-API-DMAC7.html)
RU (1) RU2382780C2 (cg-RX-API-DMAC7.html)
TW (2) TW201217332A (cg-RX-API-DMAC7.html)
WO (1) WO2005085236A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200607634B (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL204619B1 (pl) * 1998-03-19 2010-01-29 Vertex Pharma Pochodna peptydowa, kompozycja farmaceutyczna zawierająca taką pochodną i zastosowanie pochodnej peptydowej
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
AU2005223767B2 (en) * 2004-03-12 2011-12-01 Vertex Pharmaceuticals Incorporated Processes and intermediates for the preparation of aspartic acetal caspase inhibitors
PL217743B1 (pl) * 2004-05-15 2014-08-29 Vertex Pharma Zastosowanie inhibitorów ICE/kaspazy-1 do leczenia napadów i konwulsji w epilepsji oraz zawierające je kompozycja farmaceutyczna i zestaw
CN1980658A (zh) * 2004-05-27 2007-06-13 沃泰克斯药物股份有限公司 治疗自身炎性疾病的ice抑制剂
US9365612B2 (en) 2010-01-29 2016-06-14 United States Of America As Represented By The Secretary, Department Of Health And Human Services Caspase inhibitors
US9956260B1 (en) 2011-07-22 2018-05-01 The J. David Gladstone Institutes Treatment of HIV-1 infection and AIDS
MX2016014731A (es) 2014-05-12 2017-05-04 Conatus Pharmaceuticals Inc Tratamiento de las complicaciones de la enfermedad cronica del higado con enfermedades de caspasa.
WO2017079566A1 (en) 2015-11-05 2017-05-11 Conatus Pharmaceuticals, Inc. Caspase inhibitors for use in the treatment of liver cancer
KR20180101418A (ko) 2015-12-31 2018-09-12 코나터스 파마슈티칼스, 인크. 간 질환의 치료에서의 카스파제 억제제의 사용 방법
CN105853408B (zh) * 2016-04-15 2018-12-04 浙江大学 苯酰胺衍生物在制备Caspase-1抑制剂中的应用
MX2019003889A (es) 2016-10-05 2019-08-12 Novartis Ag Composiciones de combinacion que comprenden agonistas de fxr para tratar o prevenir una enfermedad o trastorno fibrotico o cirrotico.
WO2022123062A1 (en) 2020-12-11 2022-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Blocking caspase and/or fasl for preventing fatal outcome in covid-19 patients
WO2024044098A2 (en) * 2022-08-23 2024-02-29 Alexion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement mediated disorders

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) * 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
GB9005014D0 (en) * 1990-03-06 1990-05-02 Janssen Pharmaceutica Nv N.(4.piperidinyl)(dihydrobenzofuran or dihydro.2h.benzopyran)carboxamide derivatives
US5716929A (en) * 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
ES2152414T3 (es) * 1994-07-22 2001-02-01 Byk Gulden Lomberg Chem Fab Dihidrobenzofuranos.
US6297269B1 (en) * 1995-06-06 2001-10-02 Pfizer Inc. Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
JP3492703B2 (ja) * 1996-09-12 2004-02-03 アイドゥン ファーマシューティカルズ,インコーポレイテッド システインプロテアーゼのICE/ced―3ファミリーの阻害剤としてのC―末端変性(N―置換)―2―インドリルジペプチド
ATE310528T1 (de) * 1996-09-12 2005-12-15 Idun Pharmaceuticals Inc Hemmung der apoptose unter verwendung von inhibitoren der interleukin-1 beta converting enzym (ice)/ced-3 familie
FR2766188B1 (fr) 1997-07-15 2000-02-11 Hoechst Marion Roussel Inc Nouveau procede de preparation de derives amines d'alkyloxy furanone, composes issus de ce procede et utilisation de ces composes
PL204619B1 (pl) * 1998-03-19 2010-01-29 Vertex Pharma Pochodna peptydowa, kompozycja farmaceutyczna zawierająca taką pochodną i zastosowanie pochodnej peptydowej
US7053056B2 (en) 1998-07-02 2006-05-30 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6630473B1 (en) 1999-01-29 2003-10-07 Senju Pharmaceutical Co., Ltd. Anti-inflammatory agents and inhibitors against increase in ocular tension caused by irradiation with lasers, containing 1,4-dihydropyridine derivatives
ATE472539T1 (de) * 2000-04-24 2010-07-15 Vertex Pharma Verfahren und zwischenprodukte zur herstellung von substituierten asparaginsäure-acetalen
PE20011350A1 (es) * 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
NZ516918A (en) 2000-05-23 2004-06-25 Vertex Pharma Caspase inhibitors and uses thereof
DE60131160T2 (de) 2000-06-07 2008-08-07 Vertex Pharmaceuticals Inc., Cambridge Caspase-inhibitoren und ihre verwendungen
JP2004509120A (ja) 2000-09-13 2004-03-25 バーテックス ファーマシューティカルズ インコーポレイテッド カスパーゼ阻害剤およびそれらの用途
MXPA03009647A (es) 2001-04-19 2004-01-29 Vertex Pharma Heterociclildicarbamidas como inhibidores de caspasa.
US6645994B1 (en) 2001-06-01 2003-11-11 Alcon, Inc. Method of treating dry eye disorders
EP1485107A1 (en) 2002-02-11 2004-12-15 Vertex Pharmaceuticals Incorporated Phospholipids as caspase inhibitor prodrugs
AU2005223767B2 (en) * 2004-03-12 2011-12-01 Vertex Pharmaceuticals Incorporated Processes and intermediates for the preparation of aspartic acetal caspase inhibitors

Similar Documents

Publication Publication Date Title
JP2005533825A5 (cg-RX-API-DMAC7.html)
RU2005102094A (ru) Ингибиторы каспазы и их применение
CA2067221C (en) Fused pyrimidine derivative, process for preparation of same and pharmaceutical preparation comprising same as active ingredient
DE69913047T2 (de) Verfahren zur Herstellung von Benzamid-Derivaten
JP2003534325A5 (cg-RX-API-DMAC7.html)
JP2006513220A5 (cg-RX-API-DMAC7.html)
WO2001085730A1 (en) Pyrido' 1,2-alpha pyrazine and piperidine derivatives as ligands for the neuropeptide y y5 receptor
JP2002514649A (ja) エポチロン誘導体、それらの製造方法、並びにそれらの使用
JPS62198683A (ja) 置換チエノイミダゾ−ル誘導体およびその製法
RU2006134258A (ru) Ингибиторы каспаз и их применение
CA2156961A1 (en) Use of substituted 4-phenyl-6-amino-nicotinic acid derivatives as medicaments
DE69128477T2 (de) Benzopyranderivat
JPH06500085A (ja) ベンズイミダゾール、その製造および使用法
CA2076982A1 (en) Pyridonecarboxylic acid derivatives
RU2007123615A (ru) Производные 3-[2-(3-ациламино-2-оксо-2н-пиридин-1-ил)-ацетиламино]-4-оксо-пентановой кислоты и их применение в качестве ингибиторов каспазы
JPH03193799A (ja) 3―(l―ピログルタミル)―l―チアゾリジン―4―カルボン酸およびその誘導体の製造方法
CN111233750A (zh) 一种3,3-二氟-1,2,3,6-四氢哌啶类衍生物及其制备方法
KR102793047B1 (ko) 4-치환 옥사졸로퀴놀리논 유도체, 약학적으로 허용되는 이의 염인 화합물 및 이를 유효성분으로 포함하는 천식 또는 아토피 등의 알러지성 질환의 예방 또는 치료용 약학 조성물
JP2719841B2 (ja) チオ尿素誘導体及びその製造方法
JPS5810583A (ja) 5,6,7,7a−テトラヒドロ−4H−チエノ(3,2−c)−ピリジン−2−オン誘導体の製法
CA2008059A1 (en) Cephalosporin derivatives and processes for their preparation
US20090227645A1 (en) Pharmaceutical compositions of valdecoxib
JP5127114B2 (ja) Cf3−chf−cf2−nr2合成方法
KR102888694B1 (ko) 알킬-d-알라니네이트의 제조방법
JP2009541231A5 (cg-RX-API-DMAC7.html)